SU14813
| CAS No. | 627908-92-3 | Cat. No. | BCP27700 |
| Name | SU14813 | ||
| Synonyms | SU-14813;SU 14813; SU014813; SU-014813; SU 014813; | ||
| Formula | C23H27FN4O4 | M. Wt | 442.48 |
| Description | SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3) (1). SU14813 was developed as a next-generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | PDGFR VEGFR c Kit | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.